Shots:
- Pfizer has reported P-III (HER2CLIMB-05) trial data assessing Tukysa (n=326) vs PBO (n=328), both in combination with trastuzumab & pertuzumab, as a maintenance therapy for pts with HER2+ MBC following induction therapy in the 1L setting
- Trial met its 1EP with a significant improvement in the investigator-assessed PFS & showed favorable safety; data to be presented in a future meeting & shared with global health authorities
- Tukysa (PO) is an HER2 tyrosine kinase inhibitor, previously approved with trastuzumab & capecitabine for adults with HER2+ advanced or metastatic breast cancer, incl. those with brain metastases after prior anti-HER2 therapies
Ref: Pfizer| Image: Pfizer| Press Release
Related News:- Pfizer Expands into Obesity Treatments with ~$7.3B Metsera Acquisition
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
